The post Top Expert Hints at XRP Price Dip Below $1, But There’s a Catch appeared on BitcoinEthereumNews.com. Key Insights: XRP price slipped over 3% today and The post Top Expert Hints at XRP Price Dip Below $1, But There’s a Catch appeared on BitcoinEthereumNews.com. Key Insights: XRP price slipped over 3% today and

Top Expert Hints at XRP Price Dip Below $1, But There’s a Catch

Key Insights:

  • XRP price slipped over 3% today and exchanged hands at $2.09.
  • The US Spot XRP ETF has continued to witness positive fund flows.
  • Analyst warns of a Ripple coin price dip to $1 or even lower.

XRP price has recorded a significant decline today, losing more than 3.5%, which has raised concerns among market participants. Amid the topsy-turvy scenario, a renowned expert has warned of a potential drop to $1 or even lower.

This latest Ripple coin price prediction has further dampened the market sentiment. In other words, the gloomy forecasts might also have triggered the recent selling pressure in the market, causing the dip in the asset’s value.

Meanwhile, the institutional interest remains robust in the crypto, as evidenced by the recent fund flow into the US Spot XRP ETF. The investment instrument has continued to witness funds entering, suggesting that the institutions are optimistic about the potential future movement of the coin.

In addition, the recent gloomy forecast over a significant dip in XRP price comes despite the bullish sentiment hovering in the market. For context, the expert, who has hinted towards the dip in “worst-case scenario,” said that the dip would provide a buy-the-dip opportunity to market participants.

XRP Price Slips Despite Sustained Institutional Interest

XRP price was down more than 3% and exchanged hands at $2.09 at the time of writing. The recent dip in Ripple coin price has fueled concerns, especially as the broader market has recorded a robust rally today.

It’s worth noting that the crypto has slipped from its daily high of $2.16, while touching a 24-hour low of $2.07. Notably, the trading volume of the crypto also fell more than 25% to $3.2 billion at the time of writing.

With this recent dip, XRP price weekly chart showed a plunge of nearly 3.5%, suggesting a waning risk-bet appetite of traders. However, the weekly chart showed a surge of over 8%, as the crypto has recovered from a monthly low of $1.77.

It’s worth noting that Ripple coin has rallied to as high as $2.44 in recent weeks, which has triggered optimism among market participants. In addition, the recent US Spot XRP ETF fund flow data also suggests sustained interest of the institutions towards the crypto.

For context, the US Spot XRP ETF has recorded an inflow of $10.63 million on Wednesday, January 14. With this, the cumulative total net inflow has hit $1.26 billion since launch, SoSoValue data showed.

XRP ETF Fund Flow Data | Source: SoSoValue

What’s Next for Ripple Coin?

Amid the recent dip in XRP price, a renowned expert has hinted at a brutal crash ahead. However, despite the warning, the expert remains optimistic about the potential future movement of the coin.

For context, in a recent analysis shared on X, analyst EGRAG CRYPTO assessed the worst-case scenario, donning the “Bears hat” to objectively evaluate the situation.

According to EGRAG CRYPTO, if XRP price follows historical patterns, it could experience a 31% to 47% drawdown. As per his worst-case zone, the target would be around $1.40-$1.20, or even $0.9.

However, the expert remains bullish on the long-term prospects of Ripple coin, citing strong fundamentals and structure. Besides, he is confident that the current bull cycle isn’t over, and the macro trajectory points towards an XRP price rally to double digits.

XRP Price Prediction | Source: EGRAG CRYPTO, X

Considering that, it seems that Ripple coin might face a pullback in the near future. However, for the long term, the experts are optimistic over a strong run for the asset, potentially to $10 and beyond.

Source: https://www.thecoinrepublic.com/2026/01/15/top-expert-hints-at-xrp-price-dip-below-1-but-theres-a-catch/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26